One year follow up comparison of three advanced hybrid closed
loop systems in adolescent patients with type 1 diabetes

a 2025

One year follow up comparison of three advanced hybrid closed loop systems in adolescent patients with type 1 diabetes

KONEČNÁ, Petra; Jana VYŽRÁLKOVÁ; Beáta KREJČÍŘOVÁ; Klára HÁJKOVÁ; Dagmar PROCHÁZKOVÁ et al.

Základní údaje

Originální název

One year follow up comparison of three advanced hybrid closed loop systems in adolescent patients with type 1 diabetes

Autoři

KONEČNÁ, Petra; Jana VYŽRÁLKOVÁ; Beáta KREJČÍŘOVÁ; Klára HÁJKOVÁ a Dagmar PROCHÁZKOVÁ

Vydání

Diabetes Research and Clinical Practice, 2025

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30202 Endocrinology and metabolism

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.diabres.2025.112823

Klíčová slova česky

hybrid closed loop systems adolescent patients type 1 diabetes

Změněno: 19. 3. 2026 15:13, Mgr. Tereza Miškechová

Anotace

V originále

Background: MiniMed 780G, Control-IQ and CamAPS FX are currently the three advanced hybrid closed loop (AHCL) systems most commonly used in pediatric patients with type 1 diabetes (T1D) in the Czech Republic. Adolescents and young adults are the group with the highest HbA1C values, often unable to reach recommended glycemic targets. Aim: The aim of the present work was to retrospectively compare data from continuous glucose monitoring in adolescent patients one year after initiation of AHCL (MiniMed 780G, Control-IQ and CamAPS FX) therapy. Method: Fifty-five adolescent (19 MiniMed 780G system, 15 Control-IQ , 21 CamAPS FX), M: F 23: 22, mean age 15.7 years) with T1D, previously treated with Predictive Low Glucose Suspend (PLGS) systems or Multiple Daily Injections (MDI) and then upgraded to AHCL have been enrolled. Glycemic control (GMI and time in ranges, mean glucose value, standard deviation, coefficient of variation) and AHCL characteristic (total insulin dose, basal/bolus ratio) were analyzed at baseline and at 3, 6 and 12 months after initiation of the AHCL system. Results: For all AHCL systems, there was a significant increase in time in range (TIR) after 3 months of therapy from 65.1 to 80.1 % (p < 0.0004) and from 74.8 to 79.6 % (p < 0.021 ) and 64.6 to 79.6  %(p < 0.001). The MiniMed 780 and the CamAPS FX group achieved significant increase in TIR over the year as well as a reduction in total time below range (TBR). For the CamAPS group, there was also a significant reduction in TAR and the Tandem Control-IQ group, there was a significant reduction in TBR during the whole year. In patients treated with the MiniMed 780G insulin pump, there were significant reductions in TBR during 6 and 12 months from the start of the treatment compared to the CamAPS group. Severe hypoglycaemia and diabetic ketoacidosis were not observed. Conclusion: All AHCL systems are safe and lead to improved glycemic control in adolescent patients with T1D especially during the first 3 months after initiation of AHCL therapy.

Citovat

KONEČNÁ, Petra; Jana VYŽRÁLKOVÁ; Beáta KREJČÍŘOVÁ; Klára HÁJKOVÁ a Dagmar PROCHÁZKOVÁ. One year follow up comparison of three advanced hybrid closed loop systems in adolescent patients with type 1 diabetes. In Diabetes Research and Clinical Practice. 2025. Dostupné z: https://doi.org/10.1016/j.diabres.2025.112823.

@proceedings{2542939,
   author = {Konečná, Petra and Vyžrálková, Jana and Krejčířová, Beáta and Hájková, Klára and Procházková, Dagmar},
   booktitle = {Diabetes Research and Clinical Practice},
   doi = {https://doi.org/10.1016/j.diabres.2025.112823},
   language = {eng},
   title = {One year follow up comparison of three advanced hybrid closed loop systems in adolescent patients with type 1 diabetes},
   year = {2025}
}

TY  - CONF
ID  - 2542939
AU  - Konečná, Petra - Vyžrálková, Jana - Krejčířová, Beáta - Hájková, Klára - Procházková, Dagmar
PY  - 2025
TI  - One year follow up comparison of three advanced hybrid closed loop systems in adolescent patients with type 1 diabetes
N2  - Background: MiniMed 780G, Control-IQ and CamAPS FX are currently the three advanced hybrid closed loop (AHCL) systems most commonly used in pediatric patients with type 1 diabetes (T1D) in the Czech Republic. Adolescents and young adults are the group with the highest HbA1C values, often unable to reach recommended glycemic targets. Aim: The aim of the present work was to retrospectively compare data from continuous glucose monitoring in adolescent patients one year after initiation of AHCL (MiniMed 780G, Control-IQ and CamAPS FX) therapy. Method: Fifty-five adolescent (19 MiniMed 780G system, 15 Control-IQ , 21 CamAPS FX), M: F 23: 22, mean age 15.7 years) with T1D, previously treated with Predictive Low Glucose Suspend (PLGS) systems or Multiple Daily Injections (MDI) and then upgraded to AHCL have been enrolled. Glycemic control (GMI and time in ranges, mean glucose value, standard deviation, coefficient of variation) and AHCL characteristic (total insulin dose, basal/bolus ratio) were analyzed at baseline and at 3, 6 and 12 months after initiation of the AHCL system. Results: For all AHCL systems, there was a significant increase in time in range (TIR) after 3 months of therapy from 65.1 to 80.1 % (p < 0.0004) and from 74.8 to 79.6 % (p < 0.021 ) and 64.6 to 79.6  %(p < 0.001). The MiniMed 780 and the CamAPS FX group achieved significant increase in TIR over the year as well as a reduction in total time below range (TBR). For the CamAPS group, there was also a significant reduction in TAR and the Tandem Control-IQ group, there was a significant reduction in TBR during the whole year. In patients treated with the MiniMed 780G insulin pump, there were significant reductions in TBR during 6 and 12 months from the start of the treatment compared to the CamAPS group. Severe hypoglycaemia and diabetic ketoacidosis were not observed. Conclusion: All AHCL systems are safe and lead to improved glycemic control in adolescent patients with T1D especially during the first 3 months after initiation of AHCL therapy.
ER  -

KONEČNÁ, Petra; Jana VYŽRÁLKOVÁ; Beáta KREJČÍŘOVÁ; Klára HÁJKOVÁ a Dagmar PROCHÁZKOVÁ. One year follow up comparison of three advanced hybrid closed loop systems in adolescent patients with type 1 diabetes. In \textit{Diabetes Research and Clinical Practice}. 2025. Dostupné z: https://doi.org/10.1016/j.diabres.2025.112823.

Přehled o publikaci